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Introduction
Heart transplantation (HTx) remains the definitive treatment for advanced heart failure (HF), offering a median survival after HTx of more than 13 years 1 . Within 5 years, however, ~30%
of the patients develop cardiac allograft vasculopathy (CAV), an important contributor to adverse outcome after HTx 2 . Clinically, CAV resembles coronary heart disease, but is pathologically distinct from the usual coronary atherosclerosis and may affect any graft vessel, with concentric, progressive thickening along the length of the vessels that ultimately leads to ischemia, HF and death 3 . Multiple factors contribute to CAV development, including immunologic (e.g., chronic rejection process) and non-immune related responses (e.g., hyperlipidemia and viral infection), but the pathogenesis is incompletely understood.
Everolimus (EVR) is an alternative or supplement to calcineurin inhibitor (CNI)
based immunosuppressive regimen after HTx and reduces the incidence and progression of CAV [4] [5] [6] . EVR, a mammalian target of rapamycin (mTOR) inhibitor, has antiproliferative effects on lymphocytes, vascular smooth muscle cells (VSMCs), endothelial cells (ECs) and fibroblasts 7 and attenuates the activation and inflammatory response of neutrophils in vitro 8 .
However, the clinical benefit of EVR in HTx correlates poorly with changes in circulating inflammatory and vascular markers, and the mechanism by which EVR slows CAV progression remains unrevealed 5 .
The Notch signaling pathway is essential for communication between neighboring cells 9 and processes known to contribute to CAV 10 , like EC activation 11 , accumulation and activation of immune cells 12 , proliferation of VSMC and extracellular matrix (ECM) remodeling 13, 14 and T cell activation 15 . Activation or inhibition of Notch signaling depends on the configuration and interactions of canonical Notch ligands 16 . 
Materials and Methods
Patient population
Two adult HTx cohorts were included: i) de novo HTx recipients from the Scandinavian heart transplant everolimus de novo study with early CNI avoidance (SCHEDULE) 4 , and ii) maintenance HTx recipients from the NOrdic Certican Trial in HEart and Lung Transplantation (NOCTET) 30 .
The SCHEDULE trial (ClinicalTrials.gov NCT01266148) was a 1 year, controlled and randomized multicenter trial and has been reported in detail 4 . 
Results
Patient population
Baseline demographics and characteristics were comparable between the two treatment groups of de novo HTx recipients (SCHEDULE population), except for measured glomerular filtration rate, hsCRP and total cholesterol that were higher and uric acid and NT-proBNP that were lower in the EVR group (Table 1) . For maintenance HTx recipients (NOCTET population), no differences in baseline demographics and characteristics were found (Table   1 ). For comparison , 20 healthy control subjects were recruited. Controls (mean age±SD:
59.4±8.8 years) were of similar age as the NOCTET population (58.9±9.3), but nonsignificantly older than the SCHEDULE population (50.5±13.7, p=0.11). Further, creatinine in the controls was lower (76±11 mol/l) compared to both SCHEDULE (111±41mol/l, p<0.001) and NOCTET (121±26mol/l, p<0.001). Women represented 35% of controls, which was not statistically different from SCHEDULE (24%) or NOCTET (12%) (Chi square p=0.11).
Notch ligands in plasma at baseline
Compared to healthy controls and adjusting for differences in age and creatinine, baseline plasma DLL1 levels were higher in de novo (SCHEDULE) (p<0.01) and in maintenance (Figure 1 ).
Baseline POSTN levels were also higher in both groups of HTx recipients compared to controls, but in contrast to DLL1, the highest levels of POSTN were seen in de novo HTx For DLK1, no significant differences were found ( Figure 1 ).
Effect of EVR on Notch ligands in plasma
. A significant overall treatment effect was observed in the temporal course of circulating DLL1 for each study population ( Figure 2 ). In de novo HTx recipients (SCHEDULE) plasma levels of DLL1 decreased after 6 months of EVR treatment and remained low compared to baseline levels, but above those of healthy controls, throughout the study. Comparing the change in DLL1 after adjusting for baseline DLL1 levels and change in kidney function (i.e., creatinine) in the same period revealed a significantly larger decrease in the EVR group at all timepoints. Among maintenance HTx recipients (NOCTET) a similar, but less distinct pattern was observed with a significant treatment effect at 1year follow-up.
No treatment effects were observed for POSTN or DLK1 (Figure 2 ). POSTN levels declined after commencing on either of the immunosuppressive regimens in de novo HTx (SCHEDULE) recipients and remained low, but above those of healthy controls, for both treatment groups compared to baseline ( Figure 2 ). In contrast, POSTN increased compared to baseline at all subsequent timepoints in both treatment groups in maintenance HTx recipients (NOCTET) (Figure 2 ). Plasma DLK1 remained stable and comparable to levels in healthy controls in both treatment arms and study populations ( Figure 2 ).
While DLL1 displayed similar profiles in SCHEDULE and NOCTET, POSTN exhibited a marked early decline in SCHEDULE, independent of study arm. The level of POSTN at 1 and 3 years in SCHEDULE was quite similar to NOCTET levels (i.e., median 4.7 years post HTx) and it seems that at 6 months, "steady state" levels of POSTN are achieved. The reason for this pattern is unclear, but as POSTN is induced during tissue injury and during ECM remodeling 34 , we suggest that the initial high POSTN levels after HTx reflect ongoing ECM remodeling.
Notch ligands and acute rejections
Similar to the original report 31 , there was a trend association between biopsy-proven acute rejection (BPAR) and the use of EVR (32% vs. 13%, p=0.056), EVR and CNI, respectively).
As depicted in Supplemental Table 1 , we observed, however, no difference in change in DLL1 between patients with and without BPAR, although there was a trend toward lower DLL1 levels in patients who experienced BPAR within the first year (p=0.090). No differences in change-or 1-year levels of DLL1 in relation to BPAR were observed within the treatment arms. For the other ligands, the decline in POSTN during 1 year follow-up was larger in those who experienced BPAR.
DLL1 and CAV development
Recently, we reported attenuated CAV development in the EVR group of de novo HTx recipients (SCHEDULE) 5 . Herein, we observed a treatment effect for DLL1. We therefore evaluated the relationship between change in DLL1 (∆DLL1) and CAV development in the SCHEDULE population. A positive correlation between ∆DLL1 and change in maximal intimal thickness (∆MIT) from baseline to 1 (r=0.31, p=0.016) and 3 years (r=0.39, p=0.006) was noted, primarily reflecting changes in the CNI group ( Figures 3A and 3B ). However, we found no correlation between MIT and DLL1 levels at the individual time points. ∆DLL1 could potentially reflect improved allograft function, but correlations with changes in allograft function [i.e., left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), peak early diastolic mitral inflow velocity/ peak late diastolic mitral inflow velocity (E/A ratio) and NT-proBNP] were poor for both ∆MIT and ∆DLL1 (Supplemental Table 2 ). However, ∆DLL1 correlated with change in CRP (r=0.30, p=0.018), mainly driven by a correlation in the CNI group (r=0.58, p=0.001), and creatinine (r=0.49, p<0.001) where the correlation was present in both treatment groups (Supplemental Table 2 ).
For the whole study population, the association between ∆DLL1 and ∆MIT was sustained when treatment, ∆NT-proBNP and ∆creatinine were included in a linear regression model ( Figure 3C ). These data support that the association between changes in circulating DLL1 and MIT are independent of changes in allograft or kidney function. Moreover, changes in percent atheroma volume (∆PAV), an additional marker of CAV development also downregulated by EVR in the SCHEDULE population 5 , were also significantly correlated with ∆DLL1 at 1 and 3 years, primarily reflecting changes in the CNI group, and again, independently of allograft or kidney function ( Figure 3C ).
Effect of EVR on Notch ligand DLL1 in myocardial tissue
To assess whether the observed effects of EVR on DLL1 could be observed in the myocardium, we determined expression of mRNA for DLL1 and Notch receptors 1 and 2 in myocardial tissue from both study arms (EVR, n=14; CNI, n=18) in the SCHEDULE population. Whereas DLL1 was downregulated in the EVR group, NOTCH1/2 were similar between the groups ( Figure 4C ). Importantly, DLL1 correlated with MIT 1 year post-HTx for both study groups (n=28, r=0.40, p=0.003) ( Figures 4D and 4E) , and a similar finding was also found between DLL1 and PAV (r=0.36, p=0.057). DLL1 also correlated with LVEDD and NOTCH1 was correlated with NT-proBNP, suggesting some association with allograft function ( Figure 4D ). Figure 1A) . A similar dose-response pattern has previously been reported of rapamycin on activated T cell production of Th1/Th2 cytokines 36 , and importantly, the lower doses are relevant to targeted concentrations of EVR in the HTx patients (6-10 ng/mL in the SCHEDULE and 3-8 ng/mL in the NOCTET study). Stimulation of activated T cells with the mTOR inhibitor sirolimus, but not the CNI CsA, dampened the DLL1 and sCD25 release in a pattern similar to EVR, whereas CNI reduced sCD25 release dose dependently at 72 hours (Supplemental Figure 2) .
EVR suppresses DLL1 in activated T cells
These results suggest that the observed effects on circulating DLL1 in the EVR group may be mediated by T cells, attributable to EVR exposure rather than freedom from CNI. Moreover, in activated T cells, EVR attenuated mRNA expression of the mTOR-responsive gene UTP15
(Supplemental Figure 1B) in a similar pattern to DLL1 and sCD25, supporting a link between mTOR complex (mTORC) signaling and DLL1 release. Contrary to the effects on DLL1, the effect of EVR on mRNA levels of Notch receptors 1 and 2 was more complex with a reduction of NOTCH1 in un-activated T cells, and a dose dependent increased NOTCH1 in activated T cells at 72 hours (Supplemental Figure 3 ).
ECs and VSMCs may be sources of circulating DLL1
DLL may be released from other cells than T cells, potentially contributing to circulating DLL1 in HTx recipients. To elucidate this, we examined the release DLL1 from VSMCs, human aortic and umbilical vein ECs and cardiac fibroblasts. These experiments revealed 
Expression of DLL1 in myocardial tissue
Our findings so far show that DLL1 mRNA are expressed in myocardial tissue following ECs and VSMCs. Although we were unable to firmly establish the proximity to CAV in our specimens, the strong staining of the EC marker CD31, in the upper right corner of Figure 6C could reflect endothelial activation, a common feature of CAV 37 .
Discussion
We studied circulating Notch ligands DLL1, POSTN and DLK1 and CAV in HTx recipients complex interaction between T cells, VSMCs and ECs, also within the heart allograft.
As in chronic HF, circulating DLL1 levels at baseline in de novo HTx recipients correlated with kidney function 38 . More importantly, enhanced DLL1 levels compared to healthy controls persisted after adjustment for creatinine. DLL1 was positively correlated to systemic inflammation as reflected by hsCRP and in particular uric acid, which is markedly elevated early after HTx, potentially reflecting increased metabolic and oxidative stress 39 .
The persistently elevated DLL1 levels, suggesting enhanced Notch pathway activity, could mean that DLL1 is a marker of these processes, but also indicate that Notch signaling and DLL1 contribute to inflammation, endothelial activation and metabolic and oxidative stress in HTx recipients. Furthermore, DLL1 is central in T cell-mediated responses 40 , and differentiation and activation of T cells require DLL1-mediated Notch signaling 41 40 . While T cell activation may be important for maintaining adaptive immune responses, dysregulated T cell activation may cause maladaptive immune response characterized by extensive production of inflammatory cytokines. The release of DLL1 from activated T cells in our in vitro study may propose DLL1 to be a part in a pathogenic loop leading to enhanced T cell activation in HTx recipients and potentially maladaptive T cell responses.
A major finding was that EVR downregulated DLL1 in vivo. Our in vitro findings
show a similar effect of sirolimus, but not the CNI CsA, suggestive of mTORC involvement, but the underlying mechanisms are not clear. mTORC regulates several pathways relevant for T cell activation such as Nuclear Factor (NF)-κB, and is activated by the Akt pathway, which links T cell activation to mTORC 42 . Since the pattern of DLL1 release mimics that of sCD25, it is tempting to hypothesize that DLL1 could be directly regulated through mTORC. TNF, the prototypical activator of NF-κB, has been shown to increase DLL1 expression in fibroblast like cells 43 . Furthermore, another mTORC inhibitor, Torin-1, decreased the expression of DLL1 in vivo in colorectal cancer xenografts 44 . Moreover, the release of DSL ligands including DLL1 is achieved by shedding induced by ADAM9/10/12 [45] [46] [47] , and interestingly rapamycin (i.e., sirolimus) has been shown to inhibit ADAM10 48 and ADAM12 49, 50 . Thus, both direct mTOR mediated effects as well as protease activity that is also influenced by the mTOR pathway could contribute to DLL1 release. To illuminate the robustness of our findings, the stability of DLL1 in samples thawed more than once, could have been measured. Unfortunately, we have no data on freeze/ thaw stability for DLL1 for the present study. Finally, other Notch ligands, such as DLL3/4, Jagged 1/2 could also be involved in CAV development. Future studies should address the limiting issues of the present trial.
We conclude that in HTx recipients, DLL1 is increased and downregulated by EVRbased immunosuppression, and change in DLL1 is correlated with CAV progression. Our findings may suggest a role for Notch signaling and DLL1 in CAV progression.
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